Literature DB >> 8983269

Early detection of familial ovarian cancer.

A Dørum1, G B Kristensen, V M Abeler, C G Tropé, P Møller.   

Abstract

When ovarian cancer is detected at an early stage, prognosis is good, which has led to discussion of a screening programme. The aim of this study was to identify and examine women at high risk of familial ovarian cancer, and to evaluate the inclusion criteria and the diagnostic methods for early detection of ovarian cancer. We report the first round screening findings in a prospective study of 180 women (mean age 43.4 years) considered to be at high risk of ovarian cancer based on family history. They were subjected to gynaecological examination with transvaginal ultrasound (TVU), CA125 and breast examination. Of these, 13 women with oestrogen receptor positive breast cancer had therapeutic oophorectomy and the ovaries were histologically examined. Among 180 women examined, nine ovarian cancers (among them two found at oophorectomy because of breast cancer) (mean age 49.0 years), seven benign tumours of the ovary (mean age 48.1 years), one cancer of the cervix, and four breast cancers were diagnosed. The prevalence of ovarian cancers (5%) was significantly more than in any previous series. TVU as a diagnostic method proved useful and detected 7/9 cancers, whereas CA125 was elevated in 4/9 cancers. To our knowledge, this is the first programme which has successfully delineated a high risk group and prospectively demonstrated their high prevalence of ovarian cancer. Possible biases are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8983269     DOI: 10.1016/0959-8049(96)00137-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

1.  Screening behavior in women at increased familial risk for breast cancer.

Authors:  Yoland C Antill; John Reynolds; Mary Anne Young; Judy A Kirk; Katherine M Tucker; Tarli L Bogtstra; Shirley S Wong; Tracy E Dudding; Juliana L Di Iulio; Kelly-Anne Phillips
Journal:  Fam Cancer       Date:  2006-07-07       Impact factor: 2.375

2.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

3.  Bead-based ELISA for validation of ovarian cancer early detection markers.

Authors:  Nathalie Scholler; Meghan Crawford; Alicia Sato; Charles W Drescher; Kathy C O'Briant; Nancy Kiviat; Garnet L Anderson; Nicole Urban
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

4.  Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.

Authors:  Nathalie Scholler; Barbara Garvik; Martha Hayden-Ledbetter; Toni Kline; Nicole Urban
Journal:  Cancer Lett       Date:  2006-05-04       Impact factor: 8.679

5.  Immunohistochemical staining of tumor necrosis factor-α and interleukin-10 in benign and malignant ovarian neoplasms.

Authors:  Millena Prata Jammal; Allison Araújo DA Silva; Agrimaldo Martins Filho; Eliângela DE Castro Côbo; Sheila Jorge Adad; Eddie Fernando Candido Murta; Rosekeila Simões Nomelini
Journal:  Oncol Lett       Date:  2014-12-08       Impact factor: 2.967

6.  Cancer antigen 125 assessment using carbon quantum dots for optical biosensing for the early diagnosis of ovarian cancer.

Authors:  Walaa E Omer; Mostafa F Abdelbar; Nesma M El-Kemary; Naoki Fukata; Maged A El-Kemary
Journal:  RSC Adv       Date:  2021-09-20       Impact factor: 4.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.